Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 5/20 | 0.56 |
| ▸ | MAOB | P27338 | 4/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.56 |
| ▸ | CALML3 | P27482 | 1/20 | 0.56 |
| ▸ | SDHA | P31040 | 1/20 | 0.56 |
| ▸ | F10 | P00742 | 6/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2799453 | 0.90 | MAOA (0.55) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL2799455 | 0.90 | MAOA (0.55) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL4573661 | 0.89 | MAOA (0.70) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL4573657 | 0.89 | MAOA (0.70) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL30114894 | 0.89 | MAOA (0.70) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL13054893 | 0.88 | F10 (0.66) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL6335205 | 0.88 | MAOA (0.57) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL5917645 | 0.87 | MAOA (0.56) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL21999384 | 0.84 | MAOA (0.53) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL13232270 | 0.84 | MAOB (0.52) | MAOAMAOBLMNAPTGS1CALML3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846669-B2 | Oxazolidinone derivative and medical composition containing same | LEGOCHEM BIOSCIENCES, INC. (KR) | 2014-09-30 | — | — | US | disclosed |
| US-20140179691-A1 | NOVEL OXAZOLIDINONE DERIVATIVE AND MEDICAL COMPOSITION CONTAINING SAME | LEGOCHEM BIOSCIENCES, INC. (KR) | 2014-06-26 | — | — | US | disclosed |
| EP-2692727-A2 | NOVEL OXAZOLIDINONE DERIVATIVE AND MEDICAL COMPOSITION CONTAINING SAME | LegoChem Biosciences, Inc. (KR) | 2014-02-05 | — | — | EP | disclosed |
| WO-2012134188-A2 | NOVEL OXAZOLIDINONE DERIVATIVE AND MEDICAL COMPOSITION CONTAINING SAME | 주식회사 레고켐 바이오사이언스 (KR) | 2012-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179691-A1 | NOVEL OXAZOLIDINONE DERIVATIVE AND MEDICAL COMPOSITION CONTAINING SAME | OXA1L, PAM, ABCC1 | MAOA 3122/4885MAOB 2328/4885LMNA 2885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.